Effect of hypertension on the development of diabetic cardiomyopathy.
The effect of hypertension on the progression of diabetic cardiomyopathy was examined by attempting to induce a similar level of diabetes in both spontaneously hypertensive rats (SHR) and Wistar rats. Streptozotocin (STZ) was injected into SHR (45 mg/kg) and Wistar rats (55 mg/kg) before (eight weeks of age) and after (twelve weeks of age) the development of hypertension in the SHR. For both groups of animals, induction of diabetes resulted in depressed weight gain, increased food and fluid consumption, hypoinsulinemia, hyperglycemia, and hypertriglyceridemia. For the rats injected at eight weeks of age, an oral glucose tolerance test (OGTT) demonstrated that although the SHR were significantly less diabetic than Wistar rats, the degree of cardiac dysfunction was equivalent in both strains. These results suggest that hypertension was interacting with the diabetic condition to impair cardiac performance. Injecting SHR at twelve weeks of age increased the severity of diabetes but interestingly did not depress heart function compared with the non-diabetic SHR group. Injecting Wistar rats at this age also increased the severity of diabetes, but unlike the SHR diabetic animals, these rats still had impaired cardiac performance. These results suggest that hypertension exacerbates the cardiac dysfunction seen during diabetes, especially when SHR rats are injected with STZ prior to the elevation of blood pressure. Moreover, in the SHR, the development of LV hypertrophy at the time of STZ injection may have compensated for the damaging effects of diabetes on the myocardium, thereby enabling the heart to perform normally.
Mathis
D R
DR
Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada.
Liu
S S
SS
Rodrigues
B B
BB
McNeill
J H
JH
D000367:Age Factors; D000818:Animals; D000900:Anti-Bacterial Agents / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000502:physiology; D009202:Cardiomyopathies / Q000097:blood / Q000209:etiology*; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000139:chemically induced / Q000150:complications*; D006973:Hypertension / Q000097:blood / Q000150:complications*; D017379:Hypertrophy, Left Ventricular / Q000097:blood / Q000209:etiology; D007328:Insulin / Q000097:blood; D008297:Male; D051381:Rats; D011918:Rats, Inbred SHR; D017208:Rats, Wistar; D013311:Streptozocin / Q000097:blood; D014280:Triglycerides / Q000097:blood
D000900:Anti-Bacterial Agents; D001786:Blood Glucose; D007328:Insulin; D014280:Triglycerides; D013311:Streptozocin